secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001447362-24-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences FY2023 revenue $219.8M (+60%); Q4 $66.1M; guides 2024 $235-240M
--------------------------------------------------------------------------------

- Full-year 2023 revenue $219.8M (+60% YoY); total test reports 70,429 (+59%). Q4 revenue $66.1M (+72% YoY).
- Net loss $57.5M in 2023 vs. $67.1M in 2022; Q4 net loss $2.6M vs. $20.6M. Adjusted EBITDA $(4.4)M year, $9.4M Q4.
- Cash, cash equivalents and marketable securities $243.1M at Dec 31, 2023.
- TissueCypher test reports +328% YoY; DecisionDx-SCC +92%; IDgenetix +236%.
- 2024 revenue guidance: $235-240 million; management cites strong commercial momentum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736224000016/0001447362-24-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736224000016/cstl-20240228.htm
  HTML page:      https://secwatch.observer/filing/0001447362-24-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer